SML3998
NVP-AUY922
≥98% (HPLC)
别名:
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, 5-[2,4-Dihydroxy-5-(1-methylethyl)phenyl]-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-3-isoxazolecarboxamide, AUY922, Luminespib, VER 52296, VER-52296, VER52296
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
O=C(C1=NOC(C2=C(O)C=C(O)C(C(C)C)=C2)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC
InChI
1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
InChI 密鑰
NDAZATDQFDPQBD-UHFFFAOYSA-N
生化／生理作用
High-affinity, potent and selective heat shock protein 90 (HSP90α/β) inhibitor with anti-cancer efficacy in cultures and in vivo.
NVP-AUY922 (Luminespib; VER-52296) is a high-affinity (HSP90β Kd = 1.7 nM), potent and selective heat shock protein 90 inhibitor (HSP90α/β Ki = 9.0/8.2 nM, HSP90α/β IC50 = 7.8/21 nM) that exhibits anti-proliferation potency in cancer cultures (GI50 from 2 to 40 nM among 29 cancer lines) and anti-tumor efficacy in vivo (50-75 mg/kg/day i.p.) by inducing cancer cells G1-G2 arrest and apoptosis.
NVP-AUY922 (Luminespib; VER-52296) is a high-affinity (HSP90β Kd = 1.7 nM), potent and selective heat shock protein 90 inhibitor (HSP90α/β Ki = 9.0/8.2 nM, HSP90α/β IC50 = 7.8/21 nM) that exhibits anti-proliferation potency in cancer cultures (GI50 from 2 to 40 nM among 29 cancer lines) and anti-tumor efficacy in vivo (50-75 mg/kg/day i.p.) by inducing cancer cells G1-G2 arrest and apoptosis.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Michael Rugaard Jensen et al.
Breast cancer research : BCR, 10(2), R33-R33 (2008-04-24)
Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis. HSP90 has emerged in recent years as
Suzanne A Eccles et al.
Cancer research, 68(8), 2850-2860 (2008-04-17)
We describe the biological properties of NVP-AUY922, a novel resorcinylic isoxazole amide heat shock protein 90 (HSP90) inhibitor. NVP-AUY922 potently inhibits HSP90 (K(d) = 1.7 nmol/L) and proliferation of human tumor cells with GI(50) values of approximately 2 to 40
Brittany Epp-Ducharme et al.
Scientific reports, 11(1), 11103-11103 (2021-05-29)
The heat shock protein 90 inhibitor, luminespib, has demonstrated potent preclinical activity against numerous cancers. However, clinical translation has been impeded by dose-limiting toxicities that have necessitated dosing schedules which have reduced therapeutic efficacy. As such, luminespib is a prime
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门